Cision Newshttps://news.cision.comCision is the leading global provider of media research, distribution, monitoring and evaluation services. With over 40 locations throughout the world, Cision provides the insight, expertise and intelligence that improve performance and build reputations.Tue, 09 Jun 2026 14:01:19 GMTCision News14660https://news.cision.comhttps://news.cision.com/Content/img/news-logo.pngOrexo announces positive outcome from an in-vivo study of OX390https://news.cision.com/orexo/r/orexo-announces-positive-outcome-from-an-in-vivo-study-of-ox390,c4350133cision5365954Tue, 19 May 2026 12:00:00 GMTInvitation & Agenda: Orexo R&D Day on March 24https://news.cision.com/orexo/r/invitation---agenda--orexo-r-d-day-on-march-24,c4318007cision5319507Fri, 06 Mar 2026 15:00:00 GMTOrexo changes the organizational structure and management team to increase focus on development of new productshttps://news.cision.com/orexo/r/orexo-changes-the-organizational-structure-and-management-team-to-increase-focus-on-development-of-n,c4318005cision5319481Fri, 06 Mar 2026 14:30:00 GMTOrexo US Awarded USD 8 Million by BARDA for OX390 Development Partnershiphttps://news.cision.com/orexo/r/orexo-us-awarded-usd-8-million-by-barda-for-ox390-development-partnership,c4242807cision5221993Mon, 29 Sep 2025 18:35:00 GMTOrexo's AmorphOX technology may pave the way for intranasal GLP-1 medicationhttps://news.cision.com/orexo/r/orexo-s-amorphox-technology-may-pave-the-way-for-intranasal-glp-1-medication,c4230471cision5207736Fri, 05 Sep 2025 12:00:00 GMTSeminar: IP That Matters - Behind Orexo’s Milestone Patent Win at the US Courthttps://news.cision.com/orexo/r/seminar--ip-that-matters---behind-orexo-s-milestone-patent-win-at-the-us-court,c4226607cision5202935Fri, 29 Aug 2025 11:30:00 GMTNumber of shares and votes in Orexohttps://news.cision.com/orexo/r/number-of-shares-and-votes-in-orexo,c4172058cision5085005Mon, 30 Jun 2025 15:30:00 GMTOrexo announces positive data for powder-based intranasal vaccine formulated with the AmorphOX technologyhttps://news.cision.com/orexo/r/orexo-announces-positive-data-for-powder-based-intranasal-vaccine-formulated-with-the-amorphox-techn,c4133913cision5029035Thu, 10 Apr 2025 06:00:00 GMTOrexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitishttps://news.cision.com/orexo/r/orexo-announces-positive-topline-data-from-clinical-study-of-ox640-in-subjects-with-and-without-alle,c4089172cision4967855Fri, 10 Jan 2025 13:00:00 GMTOrexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technologyhttps://news.cision.com/orexo/r/orexo-enters-into-collaboration-with-abera-to-develop-nasal-powder-vaccines-based-on-the-amorphox-te,c4083032cision4958797Tue, 17 Dec 2024 07:00:00 GMTOrexo Interim Report Q3 2024https://news.cision.com/orexo/r/orexo-interim-report-q3-2024,c4055702cision4924187Thu, 24 Oct 2024 06:00:00 GMTOrexo: Salem Tewolde, Head of Supply Chain, on solving real problemshttps://news.cision.com/orexo/r/orexo--salem-tewolde--head-of-supply-chain--on-solving-real-problems,c4048011cision4913984Tue, 08 Oct 2024 08:00:00 GMTOrexo´s Nomination Committee for the Annual General Meeting 2025https://news.cision.com/orexo/r/orexo-s-nomination-committee-for-the-annual-general-meeting-2025,c4046784cision4912267Fri, 04 Oct 2024 06:00:00 GMTOrexo to participate in Pareto Securities´ 15th Annual Healthcare Conference 2024https://news.cision.com/orexo/r/orexo-to-participate-in-pareto-securities--15th-annual-healthcare-conference-2024,c4032221cision4892562Tue, 03 Sep 2024 07:00:00 GMTOrexo Q2 2024 Interim Reporthttps://news.cision.com/orexo/r/orexo-q2-2024-interim-report,c4015814cision4869935Wed, 17 Jul 2024 06:00:00 GMTOrexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdosehttps://news.cision.com/orexo/r/orexo-shares-new-information-on-ox124--a-high-dose-naloxone-rescue-medication-in-development-for-opi,c4015773cision4869782Tue, 16 Jul 2024 18:00:00 GMTOrexo AB´s sustainability work ranked among top 5% by EcoVadishttps://news.cision.com/orexo/r/orexo-ab-s-sustainability-work-ranked-among-top-5--by-ecovadis,c4013283cision4866353Wed, 10 Jul 2024 06:00:00 GMTOrexo: invitation to presentation of the Q2 2024 Interim Reporthttps://news.cision.com/orexo/r/orexo--invitation-to-presentation-of-the-q2-2024-interim-report,c4012455cision4865062Mon, 08 Jul 2024 12:00:00 GMTOrexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholmhttps://news.cision.com/orexo/r/orexo-publishes-prospectus-and-applies-for-admission-to-trading-of-social-bonds-on-nasdaq-stockholm,c3976889cision4816862Fri, 10 May 2024 11:30:00 GMTOrexo Q1 2024 Interim Reporthttps://news.cision.com/orexo/r/orexo-q1-2024-interim-report,c3998178cision4815108Wed, 08 May 2024 06:00:00 GMTFentanyl awareness day: The synthetic opioid fentanyl increasingly poisons young Americanshttps://news.cision.com/orexo/r/fentanyl-awareness-day--the-synthetic-opioid-fentanyl-increasingly-poisons-young-americans,c3974718cision4814087Tue, 07 May 2024 08:30:00 GMTInvitation to presentation of Orexo´s Q1 2024 Interim Reporthttps://news.cision.com/orexo/r/invitation-to-presentation-of-orexo-s-q1-2024-interim-report,c3971876cision4810140Thu, 02 May 2024 07:00:00 GMTReport from Orexo AB’s annual general meeting, 26 April 2024https://news.cision.com/orexo/r/report-from-orexo-ab-s-annual-general-meeting--26-april-2024,c3969132cision4806679Fri, 26 Apr 2024 15:30:00 GMTOrexo extends patent protection for its nasal epinephrine powder product OX640 in the UShttps://news.cision.com/orexo/r/orexo-extends-patent-protection-for-its-nasal-epinephrine-powder-product-ox640-in-the-us,c3962545cision4797497Wed, 17 Apr 2024 06:00:00 GMT